Issued 2026-08-13 at $6.74 · now $6.52 (2026-08-13, −3.3% since)
Based on its own history, a month from the 2026-08-13 close, IOVA has typically landed between $4.73 and $9.82 — a range of −29.8% to +45.8% from the issuance price $6.74.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
3,944 overlapping 1 month windows · 2010-10-15 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($6.74) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where IOVA has typically landed a month from the 2026-08-13 close of $6.74 — the range is history, not a prediction.
- now $6.52 (-3.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $6.47 (-4.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.54–$7.39
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.73–$9.82
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2013-03-07 | −83.3% | −83.3% | +0.0% |
| 2013-03-08 | −83.3% | −83.3% | +0.0% |
| 2013-03-28 | −83.3% | −83.3% | +0.0% |
| 3 best | |||
| 2013-05-08 | +300.0% | +0.0% | +500.0% |
| 2013-07-18 | +250.0% | +0.0% | +250.0% |
| 2013-07-16 | +250.0% | +0.0% | +250.0% |
3,944 overlapping windows · 2010-10-15 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer (source, as of 2026-08-14)
- 2028-03-01 — Trial primary completion: Phase 3 primary completion: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. (source, as of 2026-08-14)
- May 2028 — Trial primary completion: Phase 2 primary completion: A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. (source, as of 2026-08-14)
- December 2030 — Trial primary completion: Phase 2 primary completion: Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer (source, as of 2026-08-14)
- June 2032 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel (source, as of 2026-08-14)
- December 2032 — Trial primary completion: Phase 2 primary completion: A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~16 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.